文献速递结核与非结核分枝杆菌

贝达喹啉清除持续性结核分枝杆菌且无疾病复发:潜在治愈的体内模型

Bedaquiline kills persistent Mycobacterium tuberculosis with no disease relapse: an in vivo model of a potential cure.
PubMed 文献 · J Antimicrob Chemother · 2019-01-01

该研究利用Cornell模型小鼠比较标准抗结核方案与贝达喹啉替代乙胺丁醇方案。贝达喹啉方案在治疗开始后8周实现器官完全无细菌,并清除CF依赖的持续性杆菌,停药后经氢化可的松诱导8周无疾病复发。

要点

  • 贝达喹啉方案8周清除全部器官细菌,标准方案需14周。
  • 贝达喹啉方案8周清除CF依赖持续菌,停药后无复发。
  • 标准方案虽达细菌学阴性但持续菌未清除,存在复发风险。

核心结论

  • 贝达喹啉方案根除小鼠持续性结核感染并完全防止疾病复发。

研究设计与样本

  • 采用Cornell模型,结核分枝杆菌感染小鼠分别接受标准方案或贝达喹啉替代乙胺丁醇方案治疗14周。

主要发现

  • 贝达喹啉方案在治疗开始后8周实现全部器官cfu计数清零,早于标准方案的14周。
  • 贝达喹啉方案在8周清除CF依赖的持续性杆菌,停药后经8周氢化可的松诱导无疾病复发。

临床怎么用

  • 提示贝达喹啉方案可能缩短结核疗程并降低复发率,但需临床研究验证。

局限性

  • 研究为小鼠体内模型,结果不能直接外推至人类结核病治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Non-replicating persistent Mycobacterium tuberculosis is difficult to kill since the organisms become undetectable using our conventional diagnostic methods and tolerant to anti-TB drugs. Resuscitation-promoting factors (RPFs) have been used to 'wake up' non-replicating persisters, making them easy to detect. Bedaquiline is a novel bactericidal and sterilizing anti-TB drug with the potential to eradicate RPF-dependent persistent M. tuberculosis. We present the first head-to-head comparison between the standard anti-TB regimen and a bedaquiline-modified regimen in eradicating RPF-dependent persistent M. tuberculosis, using the well-defined Cornell Model. METHODS: M. tuberculosis-infected mice were treated for 14 weeks with either the standard regimen (rifampicin, isoniazid, pyrazinamide and ethambutol) or the same regimen where ethambutol was replaced by bedaquiline. The efficacy of both drug regimens was measured by cfu count elimination and eradication of persistent bacteria, which was evaluated using culture filtrate (CF) containing RPFs. At the end of treatment, the remaining cfu count-negative mice were administered hydrocortisone for 8 weeks. The induced disease relapse rates were determined by the percentage of mice that became positive for M. tuberculosis in the lung, spleen or both. RESULTS: The bedaquiline-containing regimen achieved total organ cfu count clearance at 8 weeks after treatment initiation, faster than the standard regimen (14 weeks). Importantly, the bedaquiline-containing regimen removed CF-dependent persistent bacilli at 8 weeks, leading to no disease relapse. CONCLUSIONS: A bedaquiline regimen eradicated persistent TB infections and completely prevented disease relapse in mice. These findings offer the potential for a faster cure for TB, with reduced relapse rate.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Hu Y, Pertinez H, Liu Y, et al. Bedaquiline kills persistent Mycobacterium tuberculosis with no disease relapse: an in vivo model of a potential cure. J Antimicrob Chemother. 2019. PMID: 30789209. doi:10.1093/jac/dkz052

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。